Stockscreener 앱 받기
5.18
1.17%
0.06
시간 외 거래:
5.17
-0.010
-0.19%
전일 마감가:
$5.12
열려 있는:
$5.2
하루 거래량:
111.87K
Relative Volume:
0.55
시가총액:
$141.65M
수익:
$61.86M
순이익/손실:
$-11.43M
주가수익비율:
-10.75
EPS:
-0.4818
순현금흐름:
$-12.52M
1주 성능:
-1.52%
1개월 성능:
+4.65%
6개월 성능:
-41.40%
1년 성능:
-24.60%
1일 변동 폭
$5.04
$5.24
1주일 범위
$4.85
$5.3499
52주 변동 폭
$4.31
$9.555
Journey Medical Corp Stock (DERM) Company Profile
명칭
Journey Medical Corp
전화
480-434-6670
주소
9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE
Compare DERM vs TAK, ZTS, TEVA, HLN, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DERM
Journey Medical Corp
|
5.18 | 140.01M | 61.86M | -11.43M | -12.52M | -0.4818 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Journey Medical Corp Stock (DERM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-25 | 개시 | H.C. Wainwright | Buy |
| 2025-07-30 | 재개 | B. Riley Securities | Buy |
| 2024-08-22 | 개시 | Rodman & Renshaw | Buy |
| 2024-06-28 | 재개 | ROTH MKM | Buy |
| 2021-12-07 | 개시 | B. Riley Securities | Buy |
Journey Medical Corp 주식(DERM)의 최신 뉴스
Assertio (ASRT) Moves 17.0% Higher: Will This Strength Last? - Yahoo Finance
Fortress Biotech CEO to speak at royalty company virtual conference - Stock Titan
10 Best Travel Insurance Companies For 2026 - Forbes
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical CorporationDERM - ChartMill
Journey Medical (NASDAQ: DERM) details 2026 virtual meeting, board and pay - Stock Titan
Vanguard reports 1.21M-share stake in Journey Medical Corp (DERM) - Stock Titan
FBIO Stock Price, Quote & Chart | FORTRESS BIOTECH INC (NASDAQ:FBIO) - ChartMill
Q1 EPS Estimates for Journey Medical Cut by HC Wainwright - MarketBeat
Journey Medical Corporation (NASDAQ:DERM) Receives Average Rating of "Hold" from Analysts - MarketBeat
Journey Medical (DERM) COO receives new RSU and option grants - Stock Titan
Journey Medical (DERM) CFO receives new RSU and stock option grants - Stock Titan
Journey Medical (DERM) CEO granted RSUs and stock options - Stock Titan
Q4 EPS Estimates for Journey Medical Raised by HC Wainwright - MarketBeat
Journey Medical Expands Emrosi™ Coverage to Over 150 Million Commercial Lives with Third Major GPO Contract - Minichart
DERM Financials: Income Statement, Balance Sheet & Cash Flow | Journey Medical Corp - Stock Titan
Journey Medical Expands Emrosi Commercial Access Across U.S. - TipRanks
Journey Medical expands Emrosi payer access to 85% of US commercial lives - TradingView
Emrosi access reaches 85% of U.S. commercial lives at Journey Medical (Nasdaq: DERM) - Stock Titan
Rosacea drug Emrosi expands access to over 150 million U.S. lives - Stock Titan
Danone Sets New Sustainability Targets with Second Phase of Impact Journey - Food & Beverage Outlook
Is Journey Med (DERM) stock a favorable investment idea | Q4 2025: EPS Beats ForecastsCrowd Entry Signals - Newser
Stock List: Research Stocks from Around the World - GuruFocus
Journey Medical Corporation (NASDAQ:DERM) Short Interest Up 31.3% in March - MarketBeat
Journey Medical Corp stock (US48113J1007): Why does its dermatology focus matter more now for U.S. i - AD HOC NEWS
DERM SEC FilingsJourney Medical Corp 10-K, 10-Q, 8-K Forms - Stock Titan
DERM Technical Analysis & Stock Price Forecast - Intellectia AI
Personal trainer shocked to find health company using his photos - BBC
Journey Medical Corp stock: What investors need to know amid volatility - AD HOC NEWS
Wasatch Advisors holds 2.13M Journey Medical (NASDAQ: DERM) — 10% stake - Stock Titan
DERM Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
DERM Stock Analysis: Journey Medical Corporation trades at $4.64 down 1.07% today - Newser
Journey Medical Corporation (NASDAQ:DERM) Given Consensus Rating of “Hold” by Analysts - Defense World
Journey Medical Corporation (NASDAQ:DERM) Given Consensus Rating of "Hold" by Analysts - MarketBeat
US Stocks Recap: Can Journey Medical Corporation be the next market leaderPortfolio Profit Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Short Squeeze: Can Journey Medical Corporation reach all time highs this year2026 Investor Takeaways & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Rare-disease voucher sale brings Fortress more than $100M - Stock Titan
Why The Journey Medical (DERM) Narrative Is Shifting With New Targets And Going Concern Risks - Yahoo Finance
KALA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Aug Update: Can Journey Medical Corporation reach all time highs this yearWeekly Investment Report & Expert Curated Trade Setups - baoquankhu1.vn
Journey Medical (NASDAQ:DERM) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Journey Medical Corporation (NASDAQ:DERM) Q4 2025 Earnings Call Transcript - Insider Monkey
HC Wainwright Forecasts Journey Medical Q1 Earnings - MarketBeat
Market Pulse: What hedge funds are buying Journey Medical CorporationQuarterly Growth Report & Verified Short-Term Plans - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Icon (ICLR) and Journey Medical Corp (DERM) - The Globe and Mail
Journey Medical (DERM) Q4 Results: Examining Essential Metrics Compared to Projections - Bitget
Journey Medical (DERM) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Journey Medical Corporation 2025 Annual Report: Dermatology Product Portfolio, FDA Approvals, Market Strategy, and Intellectual Property Overview - Minichart
Top movers analysis one hour before the close of the markets on 2026-03-26: top gainers and losers in today's session. - ChartMill
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Journey Medical Corporation Q4 2025 Earnings Call Summary - finance.yahoo.com
HC Wainwright Reaffirms Buy Rating for Journey Medical (NASDAQ:DERM) - marketbeat.com
Journey Medical Corp (DERM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.67%
2.13%
자본화:
|
볼륨(24시간):